Raltegravir is an integrase inhibitor antiviral medication used as part of combination therapy to treat HIV infection.
Raltegravir belongs to a class of medicines called integrase inhibitors. It is used to stop the replication of the human immunodeficiency virus (HIV) by blocking a key step in the virus’s life-cycle. In Hong Kong, raltegravir is available in products such as Zepdon and Isentress.
Several licensed products in Hong Kong include raltegravir as the active ingredient.
Both products are available in generic and brand versions, and they come in solid oral tablets that are taken with water. While the core ingredient is the same, manufacturers may use different inactive components, so the look and feel of the tablets can vary. All raltegravir-containing medicines are listed on the Hong Kong Department of Health’s Pharmacovigilance database and must meet the standards set by the Pharmacy and Poisons Board.
These uses reflect the approvals granted by the Hong Kong health authorities and align with international guidelines. Off-label indications are rare for raltegravir, as its activity is specific to HIV-1 integrase.
Raltegravir blocks the enzyme integrase, which HIV needs to splice its DNA into the genetic material of human cells. When this step is prevented, the virus cannot reproduce, and the amount of virus circulating in the bloodstream falls. Effects are usually seen within a few days after the first dose, helping to control infection early in the treatment course.
Most people experience only mild, temporary reactions. Typical reports include:
These symptoms are generally short-lived and do not require medical treatment unless they persist.
Rarely, raltegravir can cause more severe events. Seek urgent medical help if you notice:
Immediate assessment at a hospital or emergency department is advised for any of these signs.
People with a known hypersensitivity to raltegravir or any of its tablet ingredients should avoid the medication. Special care is also recommended for:
Raltegravir may interact with certain other drugs, especially those that affect the liver enzyme systems that process many medications. Common interaction considerations include:
For a full list of possible interactions, refer to the specific product information for Zepdon, Isentress, or any generic raltegravir tablet you are using.
Store raltegravir tablets in a dry place at room temperature, away from direct sunlight and moisture. Keep them out of reach of children. Treatment duration varies; some patients use raltegravir as a short-term starter regimen, while others remain on it for many years as part of a stable combination therapy. Always follow the instructions printed on the medication’s packaging and the guidance provided by your healthcare team. For detailed usage, dosing, and administration, refer to your specific medication’s information.
Integrase inhibitor: A type of drug that stops HIV from inserting its genetic material into a person’s cells.
cART (combination antiretroviral therapy): A treatment plan that uses several antiretroviral medicines together to control HIV infection.
This article offers general educational information about raltegravir as an active substance used in various medicines. Its purpose is to help patients better understand the ingredient and the conditions it is used to treat. It is not a substitute for professional medical advice or for the specific instructions provided with individual products. Medicines containing raltegravir may differ in formulation, strength, and directions for use. Always consult the labeling of your particular medication and follow your healthcare provider’s guidance for complete information on proper use, dosage, and safety.
